Dataset Information

Clinical value and potential targets of miR-224-5p in hepatocellular carcinoma validated by a TCGA- and GEO- based study.

ABSTRACT: OBJECTIVE:to explore clinical value and potential targets of MicroRNA-224-5p in the tumorigenesis and progression of hepatocellular carcinoma (HCC). METHODS:We evaluated the clinical value of MicroRNA-224-5p from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO). Meanwhile, target genes of MicroRNA-224-5p were predicted by bioinformatics method. The target genes of MicroRNA-224-5p were finally analyzed in Gene Ontology (GO) terms, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway annotation, and Protein-Protein Interaction (PPI) network annotation. RESULTS:MicroRNA-224-5p expression level in HCC was higher than in non-tumor tissues (SMD=1.24; 95% CI, 0.68 to 1.81; P<0.0001) and MicroRNA-224-5p might represent a diagnostic marker (overall AUC=0.92; 95% CI, 0.90 to 0.94). 262 target genes were acquired by overlapping 4927 genes predicted by more than four computational prediction tools with 1,123 down-regulated DEGs in HCC. Furthermore, gene sets enrichment analysis of the 262 overlapping genes was implemented. The mostly significant GO terms within the overlapping target genes of MicroRNA-224-5p were cellular response to chemical stimulus, plasma membrane part and coenzyme binding. KEGG pathway annotation showed the overlapping genes mostly took part in metabolic pathways. In PPI analysis, one hub gene, GNA14, stood out cause for the significant negative correlation with MicroRNA-224. CONCLUSION:MicroRNA-224-5p is upregulated in HCC and may be a prospective biomarker for diagnosis. Moreover, MicroRNA-224-5p might play an oncogenic role in HCC by targeting GNA14.

SUBMITTER: Zhang L

PROVIDER: S-EPMC6965914 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Clinical value and potential targets of miR-224-5p in hepatocellular carcinoma validated by a TCGA- and GEO- based study.

Zhang Lu L Huang Lanshan L Liang Haiwei H Zhang Rui R Chen Gang G Pang Yuyan Y Feng Zhenbo Z

International journal of clinical and experimental pathology 20170901 9

<h4>Objective</h4>to explore clinical value and potential targets of MicroRNA-224-5p in the tumorigenesis and progression of hepatocellular carcinoma (HCC).<h4>Methods</h4>We evaluated the clinical value of MicroRNA-224-5p from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO). Meanwhile, target genes of MicroRNA-224-5p were predicted by bioinformatics method. The target genes of MicroRNA-224-5p were finally analyzed in Gene Ontology (GO) terms, Kyoto Encyclopedia of Genes and Gen ...[more]

PMID: 31966887

Similar Datasets

Project description:Increasing evidence has demonstrated that microRNA (miR)‑133a‑3p is an important regulator of hepatocellular carcinoma (HCC). In the present study, the diagnostic role of miR‑133a‑3p in HCC, and the potential functional pathways, were both explored based on publicly available data. Eligible microarray datasets were collected from NCBI Gene Expression Omnibus (GEO) database and ArrayExpress database. The data related to HCC and matched adjacent normal tissues were also downloaded from The Cancer Genome Atlas (TCGA). Published studies reporting the association between miR‑133a‑3p expression and HCC were reviewed from multiple databases. By combining the data derived from three sources (GEO, TCGA and published studies), the authors analyzed the comprehensive relationship between miR‑133a‑3p expression and clinicopathological features of HCC. Eventually, putative targets of miR‑133a‑3p in HCC were selected for further bioinformatics prediction. A total of eight published microarray datasets were gathered, and the pooled results demonstrated that the expression of miR‑133a‑3p in the tumor group was lower than that in normal groups [standardized mean difference (SMD)=‑0.54; 95% confidence interval (CI), ‑0.74 to ‑0.35; P<0.001]. Consistently, the level of miR‑133a‑1 in HCC was reduced markedly compared to normal tissues (P<0.001) based on TCGA data, and the AUC value of low miR‑133a‑1 expression for HCC diagnosis was 0.670 (P<0.001). Furthermore, the combined SMD of all datasets (GEO, TCGA and literature) suggested that significant difference was observed between the HCC group and the normal control group, and lower miR‑133a‑3p expression in HCC group was noted (SMD=‑0.69; 95% CI, ‑1.10 to ‑0.29; P=0.001). In addition, the authors discovered five key genes of the calcium signaling pathway (NOS1, ADRA1A, ADRA1B, ADRA1D and TBXA2R) that may probably be targeted by miR‑133a‑3p in HCC. The study reveals that miR‑133a‑3p may function as a tumor suppressor in HCC. The prospective novel pathways and key genes of miR‑133a‑3p could offer potential biomarkers for HCC; however, the predictions require further confirmation.

Dataset Information

Clinical value and potential targets of miR-224-5p in hepatocellular carcinoma validated by a TCGA- and GEO- based study.

Publications

Clinical value and potential targets of miR-224-5p in hepatocellular carcinoma validated by a TCGA- and GEO- based study.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure